A phase 2, multicenter, open-label study of AlloStim in-situ cancer vaccine immunotherapy as 3L therapy in MSS/pMMR metastatic colorectal cancer.

Authors: Michael Har-Noy, Wirote Lausoontornsiri

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.tps317

Source: Full article

---

Abstract

TPS317